Abstract
Children with focal epilepsy compared with healthy controls were associated with statistically significant differences in the gut microbiota and carbohydrate metabolism. These differences were reduced and carbohydrate metabolism improved after effective treatment. Our research may provide new directions for understanding the role of gut microbiota in the pathogenesis of focal epilepsy and identifying better alternative treatments.
Introduction
Epilepsy affects millions of children worldwide. While many respond to standard medication, the underlying biological mechanisms—beyond electrical misfiring in the brain—remain complex. Recent research has highlighted the "brain-gut axis," a bidirectional communication system where gut bacteria influence neurological health through immune signaling and metabolic byproducts. Most existing research focuses on drug-resistant epilepsy or the ketogenic diet; this study addresses the gap by examining newly diagnosed focal epilepsy and the impact of standard monotherapy on the microbiome.
Methods
The researchers conducted a longitudinal study at Hunan Children’s Hospital, recruiting 10 children with newly diagnosed focal epilepsy and 14 healthy controls. Fecal samples were collected from the epilepsy group at two time points: before treatment and after three months of oxcarbazepine (OXC) monotherapy.
The team utilized 16S rDNA amplicon sequencing to identify bacterial communities. Bioinformatics processing via QIIME2 and DADA2 identified Amplicon Sequence Variants (ASVs), while LEfSe and Metastas identified significant taxonomic differences. Functional metabolic pathways were predicted using PICRUSt2 against the KEGG database.
Results and Discussion
The Diversity Paradox and Pro-inflammatory Signatures
Interestingly, the epilepsy group exhibited higher $\alpha$-diversity (species richness) than the control group. While high diversity is typically associated with health, in certain neurological contexts, excessive diversity has been linked to poorer cognitive performance.
At the genus level, the pre-treatment group was enriched with pro-inflammatory genera such as Escherichia/Shigella and Streptococcus. These bacteria are known to trigger cytokines like IL-6 and TNF-$\alpha$, which can cross the blood-brain barrier and increase neuronal excitability, potentially lowering the seizure threshold. Conversely, beneficial bacteria like Faecalibacterium, which produce health-promoting short-chain fatty acids, were enriched in healthy controls.
Metabolic Shifts and the Succinate Connection
Functional analysis revealed a significant metabolic shift. Pathways related to the TCA cycle and carbohydrate metabolism were upregulated in epilepsy patients. Specifically, the researchers identified succinate as a potential target; succinate accumulation has been shown in animal models to promote status epilepticus.
Treatment as a Microbial Reset
After three months of OXC treatment, the abundance of dysbiotic bacteria like Actinobacteria and Escherichia/Shigella decreased significantly. The number of significantly different genera between the epilepsy and control groups dropped from nine to four, suggesting that effective anti-epileptic treatment partially restores microbial balance and normalizes carbohydrate metabolism.
Conclusion
This study demonstrates that children with focal epilepsy possess a distinct, pro-inflammatory gut microbiome that partially corrects following standard treatment. While limited by a small sample size and associative design, these findings suggest that the gut-brain axis plays a significant role in epilepsy pathogenesis. Future research should explore whether probiotic interventions could supplement traditional anti-epileptic drugs to improve patient outcomes.
Summary updated